This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
S. epidermidis vaccine
Spero Therapeutics, LLC
Drug Names(s): S. epidermidis vaccine
Description: S. epidermidis vaccine is a vaccine being developed to prevent Staphylococcus epidermidis infections. S. epidermidis accounts for approximately 20% of all staph infections in the hospital.
Biota and Nabi
In April 2012, Nabi Biopharmaceuticals announced plans to merge with Biota Holdings. The execution of the merger implementation agreement will form a combined company to be named Biota Pharmaceuticals.
Biota and Spero
In March 2016, Biota Pharmaceuticals announced that it has completed the sale of assets related to its broad spectrum antibiotic program to a newly formed subsidiary of Spero Therapeutics. Financial terms of the transaction were not disclosed.
S. epidermidis vaccine News
Pink Sheet Nabi’s StaphVAX Development Back On Track
Additional information available to subscribers only: